Posts Tagged ‘Viking Therapeutics’

Flying Home

OW2024: Five Thoughts We’re Taking Home from ObesityWeek

November 7, 2024 — We have a lot to think about. Well over 3,000 people spent the better part of the week absorbing new science and insights into obesity – not to mention a momentous election. So as everyone sets about the task of catching up with routines, here is a quick take on five thoughts about what we’re […]

Rising Competition Gets Lilly and Novo Nordisk Down

July 27, 2024 — It’s been a rough month for investors in Lilly and Novo Nordisk – largely because of the prospects for rising competition to their wildly successful obesity medicines. Accelerating VK2735 This week, Viking Therapeutics announced they are accelerating development of injectable form of VK2735, a dual agonist that works on both GLP-1 and GIP receptors. This […]